Gilead again backs AlloVir's T cell therapy in $127M direct offering

Kyle LaHucik

Senior Reporter

Gilead and a host of other companies are once again backing T cell immunotherapy biotech AlloVir in a direct offering that will provide the drugmaker …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Gilead again backs AlloVir's T cell therapy in $127M direct offering

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Gilead again backs AlloVir's T cell ther­a­py in $127M di­rect of­fer­ing

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Gilead again backs AlloVir's T cell therapy in $127M direct offering